MDWD MediWound

MediWound Studying the Effect of EscharEx on Biofilm Burden

MediWound Studying the Effect of EscharEx on Biofilm Burden
EN
14/10/2020

Underlying

MDWDMediWound

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediWound

 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Report Third Quarter 2025 Financial Results

MediWound to Report Third Quarter 2025 Financial Results MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2025 on Thursday, November 20, 2025. Following the release, the Company’s management will host a conference call and live webcas...

November 5, 2025 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Successfully Completes Commissioning of Expanded GMP Manufac...

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® Newly commissioned facility marks a significant development toward a sixfold production capacity increase ahead of full operational readiness by year-end 2025 YAVNE, Israel, November 3, 2025 – MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the successful completion of the commissioning process for its expanded GMP ma...

November 3, 2025 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Announces $30 Million Registered Direct Offering of Ordinary...

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into a definitive securities purchase agreement led by a prominent U.S.-based mutual fund and other healthcare-focused investors for the sale and purchase of 1,734,105 ordinary shares of the Company, par value NIS 0.07 per share, at a purchase...

September 29, 2025 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in...

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion YAVNE, Israel, September 25, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid®, the Company’s innovative e...

September 25, 2025 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations...

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin, Germany. NexoBrid®, the company’s enzymatic burn debridement therapy, will be f...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch